← All trials
NCT01459887
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2006
- Primary completion
- Dec 1, 2010
- Completion date
- Feb 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 278
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Shanghai CP Guojian Pharmaceutical Co.,Ltd.Lead sponsor
- Fujian Medical UniversityOverall official - principal investigator
- Sichuan UniversityOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Guangxi Medical UniversityOverall official - principal investigator
- Tsinghua UniversityOverall official - principal investigator
- Tianjin Medical UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityStudy director
- Sun Yat-Sen UniversityStudy chair
- Nanjing Medical UniversityOverall official - principal investigator
- Peking UniversityOverall official - principal investigator
- People's Liberation Army of ChinaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.